Showing results (81-90 of 681) with videos related to
Sort By:
Pageof 69
Clinical Lymphoma, Myeloma & Leukemia|April 17, 2019
SOHO State of the Art Updates and Next Questions: MyelofibrosisKristen Pettit, Srdan Verstovsek, Moshe TalpazClinical Advances in Hematology & Oncology : H&O|February 13, 2023
A review of essential thrombocythemia and its complicationsRodrick Babakhanlou, Lucia Masarova, Srdan VerstovsekHematology (Amsterdam, Netherlands)|April 18, 2012
Breakthroughs in myeloproliferative neoplasmsFabio P S Santos, Srdan VerstovsekCancer|April 10, 2004
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignanciesAmit Panwalkar, Srdan Verstovsek, Francis GilesCurrent Opinion in Hematology|January 11, 2017
'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategiesRita Assi, Srdan Verstovsek, Naval DaverAnnals of Hematology|August 16, 2017
The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a reviewDevendra Kc, Lorenzo Falchi, Srdan VerstovsekClinical Advances in Hematology & Oncology : H&O|November 10, 2023
Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasmsIvan Krecak, Srdan Verstovsek, Marko LucijanicFuture Oncology (London, England)|September 17, 2011
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosisAlen Ostojic, Radovan Vrhovac, Srdan VerstovsekBlood Reviews|November 25, 2010
JAK2 inhibitors: what's the true therapeutic potential?Fabio P S Santos, Srdan VerstovsekCurrent Opinion in Hematology|February 7, 2013
What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?Fabio P S Santos, Srdan VerstovsekPageof 69